(Reuters) -Canada's health regulator has approved Novo Nordisk's diabetes drug, Ozempic, for reducing the risk of kidney ...

Diabetic medicine Ozempic now approved by Health Canada to reduce the risk of further kidney decline among patients with Type ...

Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between ...

Health Canada has approved Ozempic in an effort to help reduce the risk of kidney decline for patients living with Type 2 diabetes. The decision comes after an international clini ...

Danish drugmaker Novo Nordisk (NVO) on Tuesday said that its blockbuster drug Ozempic is now approved in Canada to reduce the risk of kidney function decline, end-stage kidney disease, and ...

Health Canada has approved Ozempic for use by Type 2 diabetes patients to reduce the risk of further kidney damage.

Novo Nordisk announced today that Ozempic® (semaglutide injection) is now approved as the first-and-only medication indicated for both the once-weekly ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

According to Google Canada, Quebec City is the first municipality in the country to partner with the web giant's Green Light ...